Brind.

Hoffmann-La Roche is gaining access to MaxCyte's platform technologies for cell therapy development.

3 reports, 2 independent Updated Aug 12

Gone quiet

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Hoffmann-La Roche is gaining access to MaxCyte's platform technologies for cell therapy development.

Who's involved

What this event is mainly about

Hoffmann-La Roche

Keep exploring

The entities involved

Hoffmann-La Roche
Swiss healthcare company
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44
- Hoffmann-La Roche opened a new R&D center in Boston.Sat 11:08

Coverage

Newest first; wire copies grouped

Aug 12themarketsdaily.com
Aug 1manilatimes.net
Jul 21manilatimes.net